Lisinopril Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 4 pharmaceutical companies such as ACCORD HLTHCARE, INVAGEN PHARMS, AZURITY and others. It is marketed under 3 brand names, including LISINOPRIL, QBRELIS, LISINOPRIL AND HYDROCHLOROTHIAZIDE. Available in 10 different strengths, such as 40MG, 2.5MG, 5MG and others, and administered through 2 routes including TABLET;ORAL, SOLUTION;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 4 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"76737","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US10039800B2","cleaned_patent_number":"10039800","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2018-08-07","legal_status":"Granted"} US10039800B2 07 Aug, 2018 Granted 06 Nov, 2035
{"application_id":"76738","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US10265370B2","cleaned_patent_number":"10265370","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2019-04-23","legal_status":"Granted"} US10265370B2 Formulation 23 Apr, 2019 Granted 06 Nov, 2035
{"application_id":"76739","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US10406199B2","cleaned_patent_number":"10406199","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2019-09-10","legal_status":"Granted"} US10406199B2 10 Sep, 2019 Granted 06 Nov, 2035
{"application_id":"76740","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US10940177B2","cleaned_patent_number":"10940177","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2021-03-09","legal_status":"Patented case"} US10940177B2 Formulation 09 Mar, 2021 Patented case 06 Nov, 2035
{"application_id":"76741","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US11179434B2","cleaned_patent_number":"11179434","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2021-11-23","legal_status":"Patented case"} US11179434B2 Formulation 23 Nov, 2021 Patented case 06 Nov, 2035
{"application_id":"76743","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US11771733B2","cleaned_patent_number":"11771733","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2023-10-03","legal_status":"Patented case"} US11771733B2 Formulation 03 Oct, 2023 Patented case 06 Nov, 2035
{"application_id":"138499","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US12128083B2","cleaned_patent_number":"12128083","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2024-10-29","legal_status":"Granted"} US12128083B2 Formulation 29 Oct, 2024 Granted 06 Nov, 2035
{"application_id":"139394","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US12186360B2","cleaned_patent_number":"12186360","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2025-01-07","legal_status":"Granted"} US12186360B2 Formulation 07 Jan, 2025 Granted 06 Nov, 2035
{"application_id":"76735","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US9463183B1","cleaned_patent_number":"9463183","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2016-10-11","legal_status":"Granted"} US9463183B2 Formulation 11 Oct, 2016 Granted 06 Nov, 2035
{"application_id":"76724","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US9616096B1","cleaned_patent_number":"9616096","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2017-04-11","legal_status":"Granted"} US9616096B2 11 Apr, 2017 Granted 06 Nov, 2035
{"application_id":"76736","ingredient":"LISINOPRIL","trade_name":"QBRELIS","family_id":"02cb2945542641aaac9f","publication_number":"US9814751B2","cleaned_patent_number":"9814751","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-11-06","publication_date":"2017-11-14","legal_status":"Patented case"} US9814751B2 Formulation 14 Nov, 2017 Patented case 06 Nov, 2035

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Lisinopril

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.